Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of iOWH032 in Dehydrating Cholera (POC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02111304
Recruitment Status : Withdrawn (Trial was never initiated due to PATH executive decision.)
First Posted : April 11, 2014
Last Update Posted : September 26, 2014
Sponsor:
Collaborator:
Bill and Melinda Gates Foundation
Information provided by (Responsible Party):
PATH

Brief Summary:
The primary hypothesis is that administration of iOWH032 to adult and pediatric males and females with acute cholera due to V. cholerae O1 reduces stool output in the first 24 hours significantly more than does the current standard of care.

Condition or disease Intervention/treatment Phase
Secretory Diarrhea Drug: iOWH032 Phase 2

Detailed Description:

This is a Phase 2, randomized, double-blind, placebo-controlled study of iOWH032 in adult patients (Part A) and then pediatric patients (Part B) with acute watery diarrhea of less than 24 hours' duration due to cholera. All subjects will be treated with standard of care (IV rehydration fluids, ORS, and azithromycin less than/equal to1 g po) in addition to study drug (iOWH032 active drug or placebo). Patients will be admitted, undergo a 4- to 6-hour screening/observation period, be randomized in the study and treated with study drug (active or placebo) for up to 3 days (ie, up to 9 doses), with a follow-up visit on Day 7.

In Part A, approximately 170 adult patients with severe dehydrating diarrhea due to cholera will be enrolled and randomized 1:1 to receive iOWH032 500 mg or placebo TID for up to 3 days. Following completion of Part A, the data and safety monitoring board (DSMB) will review the unblinded data to assess safety and efficacy and conduct a futility analysis prior to proceeding to Part B.

Following the DSMB recommendation of dose and dosing schedule for pediatric patients, Part B will be initiated. Approximately 156 pediatric patients with severe dehydrating diarrhea due to cholera will be enrolled and randomized 1:1 to receive iOWH032 or placebo at the recommended dose and dosing regimen.

The primary efficacy population for Parts A and B will consist of patients who tolerate the first 3 doses of study drug (0, 8, and 16 hours post-randomization) without vomiting and whose diagnosis is subsequently confirmed by a positive culture for V. cholerae O1.

The International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) Ethics Committee and Western Institutional Review Board (WIRB) will be informed of any serious adverse event (SAE). Occurrence of 2 or more drug-related SAEs within a group of 10 patients (20% of cumulative completed patients in the treatment group) in Part A or Part B will result in unblinding of those patients and review by the DSMB. The study can be halted, discontinued, or amended according to the recommendations of the icddr,b DSMB.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Two-Part Trial to Evaluate the Efficacy, Safety, and Tolerability of iOWH032 in the Treatment of Acute Dehydrating Diarrhea in Adult and Pediatric Patients With Cholera
Study Start Date : June 2014
Estimated Primary Completion Date : January 2016
Estimated Study Completion Date : May 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cholera Diarrhea

Arm Intervention/treatment
Active Comparator: Part A (Adults)
In Part A, approximately 170 adult patients with severe dehydrating diarrhea due to cholera will be enrolled and randomized 1:1 to receive iOWH032 500 mg or placebo TID for up to 3 days
Drug: iOWH032
Active Comparator: Part B (Pediatric)

Following completion of Part A, the data and safety monitoring board (DSMB) will review the unblinded data to assess safety and efficacy and conduct a futility analysis prior to proceeding to Part B.

Following the DSMB recommendation of dose and dosing schedule for pediatric patients, Part B will be initiated. Approximately 156 pediatric patients with severe dehydrating diarrhea due to cholera will be enrolled and randomized 1:1 to receive iOWH032 or placebo at the recommended dose and dosing regimen.

Drug: iOWH032



Primary Outcome Measures :
  1. Output (mL/kg of body weight) of unformed stools (composite) [ Time Frame: First 24-hour period following randomization ]

    The primary objectives of the study are as follows:

    • To evaluate the efficacy of iOWH032 in adults with cholera, as measured by unformed stool output in the first 24 hours after administration (Part A)
    • To determine an effective dose and dosing regimen of iOWH032 in children with cholera (Part A)
    • To evaluate the efficacy of iOWH032 at this recommended dose and dosing regimen in children with cholera (Part B)


Secondary Outcome Measures :
  1. Total stool output (mL/kg body weight) (composite) [ Time Frame: From randomization until the resolution of diarrhea, or until 3 days (72 hours post-dose) after administration of the first dose of study drug, whichever is sooner ]
    • Total stool output (mL/kg body weight) from randomization until the resolution of diarrhea, or until 3 days (72 hours post-dose) after administration of the first dose of study drug, whichever is sooner
    • Time to resolution of diarrhea
    • Incidence of diarrhea resolution within 48 hours and within 72 hours from the time of administration of the first dose of study drug
    • Intake of ORS solution and plain water in mL/kg from time of randomization through the last unformed stool or until 3 days (72 hours) after administration of the first dose of study drug, whichever is sooner
    • Requirement for unscheduled IV rehydration therapy (mL/kg) after randomization
    • Sodium, potassium, chloride, cAMP, parent drug, and metabolite concentrations, all in the stool
    • Sensitivity, specificity, positive and negative predictive values, and accuracy of stool DF and RDT in the diagnosis of cholera, and the impact of antibiotic therapy on DF and RDT


Other Outcome Measures:
  1. Safety [ Time Frame: Duration of Study ]

    The safety and tolerability endpoints for this study are AEs, clinical laboratory values, physical examination results, vital signs, and ECG findings. All patients in Part A and B of the study who receive study drug will be included in the safety analysis.

    Acceptability of the iOWH032 dispersible tablet or suspension formulation will be evaluated in Part B of the study (pediatric patients).




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   5 Years to 55 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Approximately 170 adult (male and female) patients must be enrolled to ensure that 96 patients (48 active and 48 placebo) are evaluable in Part A. In Part B, approximately 156 pediatric patients will be enrolled to ensure that 120 pediatric patients (60 active and 60 placebo) are evaluable for the analysis of 24 hour stool output, the primary outcome measure.

PART A - ADULTS

***Inclusion Criteria***

A patient will be considered eligible for participation in the study if the following inclusion criteria are satisfied on admission (Day 1) to the Dhaka Hospital of icddr,b:

  • Adults aged 18 years to 55 years
  • Duration of illness: History of acute watery diarrhea of less than 24 hours' duration without fever or visible blood in feces
  • Clinical signs and symptoms of severe dehydration (>10% loss of body weight based on rehydration weight)
  • Stool RDT and/or stool DF microscopy demonstrating presence of V. cholerae
  • Must have a purging rate greater than/equal to 20 mL/kg (5 mL/kg/h) during the initial 4- to 6-hour screening/observation period, and signs of clinical dehydration must be corrected
  • Written informed consent for participation in the study (see Section 6.1.2 for details of the consent process)
  • Negative urine pregnancy test for all female patients
  • Nonpregnant and nonlactating females of childbearing potential agree to either abstain from sex or use double barrier contraception (2 contraceptive methods at a time) during the study and until 1 month after the last dose of study drug

***Exclusion Criteria***

A patient with any of the following criteria at screening for study enrollment will not qualify for the study:

  • Received antidiarrheal medication (eg, loperamide, diphenoxylate) within 7 days before screening
  • Abnormal ECG findings, with the exception of sinus tachycardia, premature atrial contractions, or ECG intervals within normal limits for sinus rate
  • Use of drugs metabolized predominantly via CYP2C9 within 7 days before screening (see Section 5.7)
  • Concomitant infection requiring antimicrobial therapy other than the study drug that may interfere with the evaluation of either the efficacy or safety of the study drug
  • Patients unwilling or unable to take part in this study or refusing to sign informed consent (patients who participate on the basis of proxy consent will be re-consented at the end of the screening/observation period; those refusing consent at that time will be excluded from further study participation)
  • Patients previously enrolled in this or any other investigational study within the past 30 days

PART B - PEDIATRIC

***Inclusion Criteria***

A patient will be considered eligible for participation in the study if the following inclusion criteria are satisfied on admission (Day 1) to the Clinical Research Ward (CRW) of Dhaka Hospital:

  • Pediatric population aged ≥ 5 years to < 18 years of age
  • Duration of illness: History of acute watery diarrhea of less than 24 hours' duration without fever or visible blood in feces
  • Clinical signs and symptoms of severe dehydration (>10% loss of body weight based on rehydration weight)
  • Stool RDT and/or stool DF microscopy demonstrating presence of V. cholerae
  • Must have a purging rate ≥5 mL/kg/h average during the initial 4- to 6-hour screening/observation period and signs of clinical dehydration must be corrected
  • Parental consent for all pediatric patients participating in the study and written informed assent for children aged 11-17 years (see Section 6.1.2 for details of the consent process)
  • Negative urine pregnancy test for female postmenarchal patients
  • Nonpregnant and nonlactating females of childbearing potential agree to either abstain from sex or use double-barrier contraception (2 contraceptive methods at a time) during the study and until 1 month after the last dose of study drug

***Exclusion Criteria***

A patient with any of the following criteria at screening for study enrollment will not qualify for the study:

  • Received antidiarrheal medication (eg, loperamide, diphenoxylate) within 7 days before screening
  • Abnormal ECG findings, with the exception of sinus tachycardia, premature atrial contractions, or ECG intervals within normal limits for sinus rate
  • Use of drugs metabolized predominantly via CYP2C9 (see Section 5.7) within 7 days before screening
  • Concomitant infection requiring antimicrobial therapy other than the study drug that may interfere with evaluation of either the efficacy or safety of the study drug
  • Children or parents/guardians unwilling or unable to take part in this study or refusing to sign informed assent/consent; applicable patients who participate on the basis of proxy assent/consent will be re-assented at the end of the screening/observation period; those refusing assent/consent at that time will be excluded from further study participation
  • Patients previously enrolled in this or any other investigational study with the past 30 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02111304


Locations
Layout table for location information
Bangladesh
International Centre for Diarrhoeal Disease Research, Bangladesh
Dhaka, Bangladesh, 1212
Sponsors and Collaborators
PATH
Bill and Melinda Gates Foundation
Investigators
Layout table for investigator information
Principal Investigator: Wasif A Khan, MBBS/MHS International Centre for Diarrhoeal Disease Research, Bangladesh
Principal Investigator: KATM Ehsanul Huq, MBBS/DTM International Centre for Diarrhoeal Disease Research, Bangladesh

Publications:
Bardhan PK, Khan WA, Ahmed S, Salam MA, Saha D, Golman D, et al. Evaluation of safety and efficacy of a novel anti-secretory anti-diarrheal agent Crofelemer (NP-303), in combination with a single oral dose of azithromycin for the treatment of acute dehydrating diarrhea caused by Vibrio cholera cholera and other Bacterial Infections: 43rd US-Japan Cooperative Medical Science Program, Kyoto, Japan, November 21, 2008.
Boschi-Pinto C, Lanata CF, Black RE. The global burden of childhood diarrhea. Matern Child Health. 2009;3: 225-243.
Cystic Fibrosis Mutation Database, 2009 [online] Available at: http://www.genet.sickkids.on.ca/cftr/app
StataCorp. POWERCAL: Stata module to perform general power and sample size calculations. http://ideas.repec.org/c/boc/bocode/s422401.html. 2013. Stata Statistical Software: Release 13. StataCorp LP, College Station, TX.
World Health Organization. The rational use of drugs in the management of acute diarrhoea in children. WHO, Geneva, 1990.

Layout table for additonal information
Responsible Party: PATH
ClinicalTrials.gov Identifier: NCT02111304     History of Changes
Other Study ID Numbers: POC Study (DDP CFT PO 202)
First Posted: April 11, 2014    Key Record Dates
Last Update Posted: September 26, 2014
Last Verified: April 2014

Keywords provided by PATH:
cholera
diarrhea
secretory diarrhea
ORS
V. cholerae O1
iOWH032
children
pharmacokinetic
Bangladesh

Additional relevant MeSH terms:
Layout table for MeSH terms
Diarrhea
Cholera
Signs and Symptoms, Digestive
Signs and Symptoms
Vibrio Infections
Gram-Negative Bacterial Infections
Bacterial Infections